Acute and Long-term Adverse Events Associated With Checkpoint Blockade

被引:9
作者
Davies, Marianne [1 ,2 ]
机构
[1] Yale Univ, Sch Nursing, POB 27399, West Haven, CT 06516 USA
[2] Yale Comprehens Canc Ctr, New Haven, CT USA
关键词
Immune checkpoint inhibitors; ICPI; Immune mediated adverse events; Immune related adverse events; IrAE; DEATH; 1; ADVANCED MELANOMA; IMMUNE; INHIBITORS; CANCER; ANTI-PD-1; MANAGEMENT; ENDOCRINE; IPILIMUMAB; THERAPY;
D O I
10.1016/j.soncn.2019.08.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: To provide an overview of the spectrum of immune-related adverse events associated with immune checkpoint therapy, including presentation, evaluation, management, and nursing considerations. Data Sources: Peer-reviewed articles, published literature, national guidelines, Internet. Conclusion: Immune checkpoint inhibitor therapies are have become a therapeutic treatment options for many cancers. These therapies promote activity of a patient's adaptive immune system to eradicate cancer. The agents are associated with a unique side-effect profile called Immune-related adverse events. Most of these are low severity. However, if they become more severe, they can be life-threatening or result in permanent organ dysfunction. The key to optimizing therapies is collaborative monitoring, evaluation, documentation, management, communication. Implications for Nursing Practice: Oncology nurses are the front line of patient care. Nurses must have a thorough understanding of the mechanism of action, potential immune-related adverse events, clinical implications, and management strategies. They are responsible for educating patients about immune checkpoint therapies and the potential side effects that may develop, triage management strategies, and coordination of care. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页数:13
相关论文
共 85 条
  • [51] Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
    Kumar, Vivek
    Chaudhary, Neha
    Garg, Mohit
    Floudas, Charalampos S.
    Soni, Parita
    Chandra, Abhinav B.
    [J]. FRONTIERS IN PHARMACOLOGY, 2017, 8
  • [52] Larkin J, 2015, NEW ENGL J MED, V373, P23, DOI [10.1056/NEJMoa1504030, 10.1056/NEJMc1509660]
  • [53] Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders
    Leonardi, Giulia C.
    Gainor, Justin F.
    Altan, Mehmet
    Kravets, Sasha
    Dahlberg, Suzanne E.
    Gedmintas, Lydia
    Azimi, Roxana
    Rizvi, Hira
    Riess, Jonathan W.
    Hellmann, Matthew D.
    Awad, Mark M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (19) : 1905 - +
  • [54] Anti-PD-1 and Anti-PDL-1 Monoclonal Antibodies Causing Type 1 Diabetes
    Mellati, Mahnaz
    Eaton, Keith D.
    Brooks-Worrell, Barbara M.
    Hagopian, William A.
    Martins, Renato
    Palmer, Jerry P.
    Hirsch, Irl B.
    [J]. DIABETES CARE, 2015, 38 (09) : E137 - E138
  • [55] Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab
    Menzies, A. M.
    Johnson, D. B.
    Ramanujam, S.
    Atkinson, V. G.
    Wong, A. N. M.
    Park, J. J.
    McQuade, J. L.
    Shoushtari, A. N.
    Tsai, K. K.
    Eroglu, Z.
    Klein, O.
    Hassel, J. C.
    Sosman, J. A.
    Guminski, A.
    Sullivan, R. J.
    Ribas, A.
    Carlino, M. S.
    Davies, M. A.
    Sandhu, S. K.
    Long, G. V.
    [J]. ANNALS OF ONCOLOGY, 2017, 28 (02) : 368 - 376
  • [56] Immune-related adverse events with immune checkpoint blockade: a comprehensive review
    Michot, J. M.
    Bigenwald, C.
    Champiat, S.
    Collins, M.
    Carbonnel, F.
    Postel-Vinay, S.
    Berdelou, A.
    Varga, A.
    Bahleda, R.
    Hollebecque, A.
    Massard, C.
    Fuerea, A.
    Ribrag, V.
    Gazzah, A.
    Armand, J. P.
    Amellal, N.
    Angevin, E.
    Noel, N.
    Boutros, C.
    Mateus, C.
    Robert, C.
    Soria, J. C.
    Marabelle, A.
    Lambotte, O.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 54 : 139 - 148
  • [57] Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma
    Moehn, Nora
    Suehs, Kurt-Wolfram
    Gingele, Stefan
    Angela, Yenny
    Stangel, Martin
    Gutzmer, Ralf
    Satzger, Imke
    Skripuletz, Thomas
    [J]. MELANOMA RESEARCH, 2019, 29 (04) : 435 - 440
  • [58] Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
    Naidoo, J.
    Page, D. B.
    Li, B. T.
    Connell, L. C.
    Schindler, K.
    Lacouture, M. E.
    Postow, M. A.
    Wolchok, J. D.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (12) : 2375 - 2391
  • [59] Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy
    Naidoo, Jarushka
    Wang, Xuan
    Woo, Kaitlin M.
    Iyriboz, Tunc
    Halpenny, Darragh
    Cunningham, Jane
    Chaft, Jamie E.
    Segal, Neil H.
    Callahan, Margaret K.
    Lesokhin, Alexander M.
    Rosenberg, Jonathan
    Voss, Martin H.
    Rudin, Charles M.
    Rizvi, Hira
    Hou, Xue
    Rodriguez, Katherine
    Albano, Melanie
    Gordon, Ruth-Ann
    Leduc, Charles
    Rekhtman, Natasha
    Harris, Bianca
    Menzies, Alexander M.
    Guminski, Alexander D.
    Carlino, Matteo S.
    Kong, Benjamin Y.
    Wolchok, Jedd D.
    Postow, Michael A.
    Long, Georgina V.
    Hellmann, Matthew D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (07) : 709 - +
  • [60] Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation
    Nguyen, Alexander T.
    Elia, Maxwell
    Materin, Miguel A.
    Sznol, Mario
    Chow, Jessica
    [J]. CORNEA, 2016, 35 (03) : 399 - 401